Resveratrol-loaded nanoparticles based on poly(epsiloncaprolactone) and poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment

Molecular Pharmaceutics

Volumn 10, Issue 10, 2013, Pages 3871-3881

  Sanna, Vanna ^a,b   Siddiqui, Imtiaz Ahmad ^b   Sechi, Mario ^a,b,c   Mukhtar, Hasan ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c Porto Conte Ricerche Srl   (Italy)

Author keywords

Nanoparticles; Poly(D,L lactic co glycolic acid) poly(ethylene glycol) conjugate; Poly(epsilon caprolactone); Prostate cancer; Resveratrol

Indexed keywords

NANOPARTICLE; POLYCAPROLACTONE; POLYGLACTIN; POLYMER; RESVERATROL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PREVENTION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CONFOCAL MICROSCOPY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; FLUORESCENCE MICROSCOPY; FOURIER TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; NANOENCAPSULATION; NANOTECHNOLOGY; PARTICLE SIZE; PRIORITY JOURNAL; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; SCANNING ELECTRON MICROSCOPY; THERMAL ANALYSIS; ZETA POTENTIAL;

CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; POLYESTERS; PROSTATIC NEOPLASMS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STILBENES;

EID: 84888338145     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400342f     Document Type: Article

References (64)

1. Pervaiz, S.; Holme, A. L. Resveratrol: its biologic targets and functional activity. Antioxid. Redox Signaling 2009, 11, 2851-2897.
2. Delmas, D.; Jannin, B.; Latruffe, N. Resveratrol: preventing properties against vascular alterations and ageing. Mol. Nutr. Food Res. 2005, 49, 377-395.
3. Tennen, R. I.; Michishita-Kioi, E.; Chua, K. F. Finding a Target for Resveratrol. Cell 2012, 148, 387-389.
4. Campagna, M.; Rivas, C. Antiviral activity of resveratrol. Biochem. Soc. Trans. 2010, 38, 50-53.
5. Das, S.; Das, D. K. Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Pat. Cardiovasc. Drug Discovery 2007, 2, 133-138.
6. Richard, T.; Pawlus, A. D.; Iglésias, M. L.; Pedrot, E.; Waffo-Teguo, P.; Mérillon, J. M.; Monti, J. P. Neuroprotective properties of resveratrol and derivatives. Ann. N.Y. Acad. Sci. 2011, 1215, 103-108.
7. Jang, M.; Cai, L.; Udeani, G. O.; Slowing, K. V.; Thomas, C. F.; Beecher, C. W.; Fong, H. H.; Farnsworth, N. R.; Kinghorn, A. D.; Mehta, R. G. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275, 218-220.
8. Dorrie, J.; Gerauer, H.; Wachter, Y.; Zunino, S. J. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res. 2001, 61, 4731-4739.
9. Estrov, Z.; Shishodia, S.; Faderl, S.; Harris, D.; Van, Q.; Kantarjian, H. M.; Talpaz, M.; Aggarwal, B. B. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 2003, 102, 987-995.
10. Hsieh, T. C.; Burfeind, P.; Laud, K.; Backer, J. M.; Traganos, F.; Darzynkiewicz, Z.; Wu, J. M. Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. Int. J. Oncol. 1999, 15, 245-252.
11. Mitchell, S. H.; Zhu, W.; Young, C. Y. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 1999, 59, 5892-5895.
12. Kuwajerwala, N.; Cifuentes, E.; Gautam, S.; Menon, M.; Barrack, E. R.; Reddy, G. P. Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res. 2002, 62, 2488-2492.
13. Sengottuvelan, M.; Viswanathan, P.; Nalini, N. Chemopreventive effect of trans-resveratrol-A phytoalexin against colonic aberrant crypt foci and cell proliferation in 1, 2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis 2006, 27, 1038-1046.
14. Oi, N.; Jeong, C. H.; Nadas, J.; Cho, Y. Y.; Pugliese, A.; Bode, A. M.; Dong, Z. Resveratrol, a red wine polyphenol, suppresses pancreatic cancer by inhibiting leukotriene Ahydrolase. Cancer Res. 2010, 70, 9755-9764.
15. Chen, Z.; Jin, K.; Gao, L.; Lou, G.; Jin, Y.; Yu, Y.; Lou, Y. Antitumor effects of bakuchiol, an analogue of resveratrol, on human lung adenocarcinoma A549 cell line. Eur. J. Pharmacol. 2010, 643, 170-179.
16. Niles, R. M.; McFarland, M.; Weimer, M. B.; Redkar, A.; Fu, Y. M.; Meadows, G. G. Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett. 2003, 190, 157-163.
17. Opipari, A. W., Jr.; Tan, L.; Boitano, A. E.; Sorenson, D. R.; Aurora, A.; Liu, J. R. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res. 2004, 64, 696-703.
18. Zoberi, I.; Bradbury, C. M.; Curry, H. A.; Bisht, K. S.; Goswami, P. C.; Roti, J. L.; Gius, D. Radiosensitizing and antiproliferative effects of resveratrol in two human cervical tumor cell lines. Cancer Lett. 2002, 175, 165-173.
19. She, Q. B.; Bode, A. M.; Ma, W. Y.; Chen, N. Y.; Dong, Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res. 2001, 61, 1604-1610.
20. Lee, K. W.; Bode, A. M.; Dong, Z. Molecular targets of phytochemicals for cancer prevention. Nat. Rev. Cancer 2011, 11, 211-218.
21. Hsieh, T. C.; Wu, J. M. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp. Cell Res. 1999, 249, 109-115.
22. Shih, A.; Zhang, S.; Cao, H. J.; Boswell, S.; Wu, Y. H.; Tang, H. Y.; Lennartz, M. R.; Davis, F. B.; Davis, P. J.; Lin, H. Y. Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-alpha. Mol. Cancer Ther. 2004, 3, 1355-1364.
23. Ratan, H. L.; Steward, W. P.; Gescher, A. J.; Mellon, J. K. Resveratroła prostate cancer chemopreventive agent? Urol. Oncol. 2002, 7, 223-227.
24. Seeni, A.; Takahashi, S.; Takeshita, K.; Tang, M.; Sugiura, S.; Sato, S. Y.; Shirai, T. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac. J. Cancer Prev. 2008, 9, 7-14.
25. Wang, T. T.; Hudson, T. S.; Wang, T. C.; Remsberg, C. M.; Davies, N. M.; Takahashi, Y.; Kim, Y. S.; Seifried, H.; Vinyard, B. T.; Perkins, S. N.; Hursting, S. D. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 2008, 29, 2001-2010.
26. Juan, M. E.; Buenafuente, J.; Casals, I.; Planas, J. M. Plasmatic levels of trans-resveratrol in rats. Food Res. Int. 2002, 35, 195-199.
27. Signorelli, P.; Ghidoni, R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J. Nutr. Biochem. 2005, 16, 449-466.
28. Zhang, L.; Gu, F. X.; Chan, J. M.; Wang, A. Z.; Langer, R. S.; Farokhzad, O. C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 2008, 83, 761-769.
29. Khushnud, T.; Mousa, S. A. Potential Role of Naturally Derived Polyphenols and Their Nanotechnology Delivery in Cancer. Mol. Biotechnol. 2013, 55 (1), 78.86, DOI: 10.1007/s12033-012-9623-7.
30. Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Delivery Rev. 2008, 60, 1615-1626.
31. Sanna, V.; Siddiqui, I. A.; Sechi, M.; Mukhtar, H. Nanoformulation of natural products for prevention and therapy of prostate cancer. Cancer Lett. 2013, 334, 142-151.
32. Jabir, N. R.; Tabrez, S.; Ashraf, G. M.; Shakil, S.; Damanhouri, G. A.; Kamal, M. A. Nanotechnology-based approaches in anticancer research. Int. J. Nanomed. 2012, 7, 4391-4408.
33. Sanna, V.; Roggio, A. M.; Piccinini, M.; Silani, S.; Marceddu, S.; Mariani, A.; Sechi, M. Development of novel cationic chitosan-and anionic alginate-coated poly(D, L-lactide-co-glycolide) nanoparticles for controlled release and light protection of resveratrol. Int. J. Nanomed. 2012, 7, 5501-5516.
34. Sahoo, S. K.; Panyam, J.; Prabha, S.; Labhasetwar, V. Residual polyvinyl alcohol associated with poly(D, L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Controlled Release 2002, 82, 105-114.
35. Siddiqui, I. A.; Mukhtar, H. Nanochemoprevention by bioactive food components: a perspective. Pharm. Res. 2010, 27, 1054-1060.
36. Siddiqui, I. A.; Adhami, V. M.; Chamcheu, J. C.; Mukhtar, H. Impact of nanotechnology in cancer: emphasis on nanochemoprevention. Int. J. Nanomed. 2012, 7, 591-605.
37. Sanna, V.; Sechi, M. Nanoparticle therapeutics for prostate cancer treatment. Maturitas 2012, 73, 27-32.
38. Sanna, V.; Roggio, A. M.; Posadino, A. M.; Cossu, A.; Marceddu, S.; Mariani, A.; Alzari, V.; Uzzau, S.; Pintus, G.; Sechi, M. Novel docetaxel-loaded nanoparticles based on poly(lactide-cocaprolactone) and poly(lactide-co- glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization and cytotoxicity studies. Nanoscale Res. Lett. 2011, 6, 260.
39. Danhier, F.; Ansorena, E.; Silva, J. M.; Coco, R.; Le Breton, A.; Préat, V. PLGA-based nanoparticles: an overview of biomedical applications. J. Controlled Release 2012, 161, 505-522.
40. Sah, H.; Thoma, L. A.; Desu, H. R.; Sah, E.; Wood, G. C. Concepts and practices used to develop functional PLGA-based nanoparticulate systems. Int. J. Nanomed. 2013, 8, 747-765.
41. Panyam, J.; Sahoo, S. K.; Prabha, S.; Bargar, T.; Labhasetwar, V. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D, L-lactide-coglycolide) nanoparticles. Int. J. Pharm. 2003, 262, 1-11.
42. Panyam, J.; Zhou, W. Z.; Prabha, S.; Sahoo, S. K.; Labhasetwar, V. Rapid endolysosomal escape of poly (DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002, 16, 1217-1226.
43. Gref, R.; Minamitake, Y.; Peracchia, M. T.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263, 1600-1603.
44. Owens, D. E., III; Peppas, N. A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307, 93-102.
45. Acharya, S.; Sahoo, S. K. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv. Drug Delivery Rev. 2011, 63, 170-183.
46. Shao, J.; Li, X.; Lu, X.; Jiang, C.; Hu, Y.; Li, Q.; You, Y.; Fu, Z. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf., B 2009, 72, 40-47.
47. Guo, L.; Peng, Y.; Yao, J.; Sui, L.; Gu, A.; Wang, J. Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice. Cancer Biother. Radiopharm. 2010, 25, 471-477.
48. Siddiqui, I. A.; Adhami, V. M.; Bharali, D. J.; Hafeez, B. B.; Asim, M.; Khwaja, S. I.; Ahmad, N.; Cui, H.; Mousa, S. A.; Mukhtar, H. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 2009, 69, 1712-1716.
49. Sanna, V.; Pintus, G.; Roggio, A. M.; Punzoni, S.; Posadino, A. M.; Arca, A.; Marceddu, S.; Bandiera, P.; Uzzau, S.; Sechi, M. Targeted biocompatibile nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells. J. Med. Chem. 2011, 54, 1321-1332.
50. Sanna, V.; Sechi, M. Nanoparticle therapeutics for prostate cancer treatment. Nanomedicine 2012, 8, S31-S36.
51. Adhami, V. M.; Malik, A.; Zaman, N.; Sarfaraz, S.; Siddiqui, I. A.; Syed, D. N.; Afaq, F.; Pasha, F. S.; Saleem, M.; Mukhtar, H. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 2007, 5, 1611-1619.
52. Betancourt, T.; Byrne, J. D.; Sunaryo, N.; Crowder, S. W.; Kadapakkam, M.; Patel, S.; Casciato, S.; Brannon-Peppas, L. PEGylation strategies for active targeting of PLA/PLGA nanoparticles. J. Biomed. Mater. Res., Part A 2009, 91, 263-276.
53. Cheng, J.; Teply, B. A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F. X.; Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28, 869-876.
54. Oganesyan, E. A.; Miroshnichenko, I. I.; Vikhrieva, N. S.; Lyashenko, A. A.; Leshkov, S. Y. Use of nanoparticles to increase the systemic bioavailability of trans-resveratrol. Pharm. Chem. J. 2010, 44, 25-27.
55. Peng, H.; Xiong, H.; Li, J.; Li, J.; Xie, M.; Liu, Y.; Bai, C.; Chen, L. Vanillin cross-linked chitosan microspheres for controlled release of resveratrol. Food Chem. 2010, 121, 23-28.
56. Sinha, V. R.; Bansal, K.; Kaushik, R.; Kumria, R.; Trehan, A. Poly-ε-caprolactone microspheres and nanospheres: an overview. Int. J. Pharm. 2004, 278, 1-23.
57. Dash, T. K.; Konkimalla, V. B. Polymeric Modification and Its Implication in Drug Delivery: Poly-ε-caprolactone (PCL) as a Model Polymer. Mol. Pharmaceutics 2012, 9, 2365-2379.
58. Donini, C.; Robinson, D. N.; Colombo, P.; Giordano, F.; Peppas, N. A. Preparation of poly(methacrylic acid-g-poly(ethylene glycol)) nanospheres from methacrylic monomers for pharmaceutical applications. Int. J. Pharm. 2002, 245, 83-91.
59. Chun, Y. S.; Kyung, Y. J.; Jung, H. C.; Kim, W. N. Thermal and rheological properties of poly(ε-caprolactone) and polystyrene blends. Polymer 2000, 41, 8729-8733.
60. Amri, A.; Chaumeil, J. C.; Sfar, S.; Charrueau, C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J. Controlled Release 2012, 158, 182-193.
61. Mehta, A. K.; Yadav, K. S.; Sawant, K. K. Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation. Curr. Drug Delivery 2007, 4, 185-193.
62. Korsmeyer, R. W.; Gurney, R.; Doelker, E.; Buri, P.; Peppas, N. A. Mechanism of solute release from porous hydrophilic polymer. J. Pharm. Sci. 1983, 15, 25-35.
63. Cai, Q.; Shi, G.; Bei, J.; Wang, S. Enzymatic degradation behavior and mechanism of poly(lactide-co-glycolide) foams by trypsin. Biomaterials 2003, 24, 629-638.
64. de Jonga, S. J.; Ariasa, E. R.; Rijkersb, D. T. S.; van Nostruma, C. F.; Kettenes-van den Boschc, J. J.; Henninka, W. E. New insights into the hydrolytic degradation of poly(lactic acid): participation of the alcohol terminus. Polymer 2001, 42, 2795-2802.